FDA/Arthritis Foundation osteoarthritis drug development workshop recap: Assessment of long-term benefit. Read more about FDA/Arthritis Foundation osteoarthritis drug development workshop recap: Assessment of long-term benefit.
Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs. Read more about Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.
Longitudinal assessment of MRI in hip osteoarthritis using SHOMRI and correlation with clinical progression. Read more about Longitudinal assessment of MRI in hip osteoarthritis using SHOMRI and correlation with clinical progression.
The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Read more about The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis.
Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Read more about Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs.
Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis--setting the record straight. Read more about Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis--setting the record straight.
